Healthcare providers who serve Medicare patients say drug price negotiations for Part B drugs could present significant operational challenges for their practices and impact their patients, according to a new survey by Avalere Health of more than 300 medical practices nationwide.

The survey, conducted among providers who serve patient populations with at least 25% Medicare beneficiaries, reveals that providers are worried about the financial sustainability of administering high-cost medications under the program’s new reimbursement structure.

Under the current system, healthcare providers operate on a “buy and bill” model, purchasing medications and receiving reimbursement from Medicare at the drug’s average sales price (ASP) plus a 6% markup to cover overhead expenses.

But under the In

See Full Page